Proton therapy developer Ion Beam Applications (IBA) posted mixed results for its 2017 fiscal year (end-December 31).
Total revenue decreased by 12.6% to 287.4 million euros ($354 million), compared with 328.7 million euros ($404.9 million) for the same period in 2016.
The company's proton therapy revenue was 233.6 million euros ($287.7 million), down 16.8% from 2016's 280.6 million euros ($345.6 million). The company attributed the decline to project rescheduling as a result of customer construction delays and a slowdown in the overall proton therapy market.
However, IBA's dosimetry revenue increased for the year by 11.9% to reach 53.8 million euros ($66.2 million), compared with 48.1 million euros ($59.2 million) in 2016, which the company attributed to the fulfillment of long-term orders and higher sales from its radiotherapy and proton therapy businesses.
